New Zealand markets close in 3 hours 43 minutes
  • NZX 50

    11,631.64
    +79.60 (+0.69%)
     
  • NZD/USD

    0.6310
    +0.0013 (+0.20%)
     
  • NZD/EUR

    0.6048
    +0.0006 (+0.09%)
     
  • ALL ORDS

    7,572.80
    +92.10 (+1.23%)
     
  • ASX 200

    7,374.70
    +90.50 (+1.24%)
     
  • OIL

    80.56
    +0.01 (+0.01%)
     
  • GOLD

    1,787.70
    +27.80 (+1.58%)
     
  • NASDAQ

    12,030.06
    +526.61 (+4.58%)
     
  • FTSE

    7,573.05
    +61.05 (+0.81%)
     
  • Dow Jones

    34,589.77
    +737.24 (+2.18%)
     
  • DAX

    14,397.04
    +41.59 (+0.29%)
     
  • Hang Seng

    18,597.23
    +392.55 (+2.16%)
     
  • NIKKEI 225

    27,968.99
    0.00 (0.00%)
     
  • NZD/JPY

    86.6630
    -0.2240 (-0.26%)
     

Vaxcyte to Participate in Upcoming Investor Conferences in May

Vaxcyte, Inc.
Vaxcyte, Inc.

SAN CARLOS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:

BofA Securities 2022 Healthcare Conference
May 10-13, 2022; Las Vegas, NV

  • Fireside chat will take place in person on Tuesday, May 10 at 5:40 p.m. ET / 2:40 p.m. PT and one-on-one meetings on Tuesday, May 10 and Wednesday, May 11.

  • A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.

UBS Global Healthcare Conference
May 23-25, 2022; New York, NY

  • One-on-one meetings will take place on Tuesday, May 24 and Wednesday, May 25.

About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com